The platform was more differentiated than the fragmented brand structure made it appear. The four core technology platforms each served distinct buyer needs across the biopharmaceutical data analytics market, and the acquisitions made during the hold period had meaningfully expanded the company's addressable service offerings. That was the story. The complexity was obscuring it.
The technical debt was real but manageable. The higher-priority risks, the ones a buy-side diligence team would surface first, could be addressed before the process opened. Where they could be fixed, we helped fix them. Where they couldn't, we acknowledged them honestly and placed them in context in the narrative. Buyers don't expect perfection, but they penalize sellers who discover the problems at the same time they did.
The platform unification roadmap was the reframe that held the multiple together. Rather than leaving a new acquirer to inherit an integration problem, we framed the roadmap as a value-creation opportunity with a clear execution path and quantifiable upside. That reframe, grounded in specifics rather than aspiration, is what allowed the company to hold its multiple through diligence.
